Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Orthofix Medical Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Orthofix Medical Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333822
| (Unaudited, U.S. Dollars, in thousands, except per share data) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Cost of sales | 61,226 | 63,588 | 118,388 | 135,615 |
| Gross profit | 149,707 | 139,533 | 289,253 | 261,152 |
| Sales, general, and administrative | 138,030 | 136,493 | 272,941 | 269,474 |
| Research and development | 15,944 | 15,934 | 31,264 | 35,700 |
| Acquisition-related amortization, impairment, and remeasurement (Note 11) | 3,867 | 3,109 | 7,618 | 20,854 |
| Operating loss | (8,134) | (16,003) | (22,570) | (64,876) |
| Interest expense, net | (6,085) | (3,950) | (11,749) | (8,456) |
| Other income (expense), net | (778) | 5,730 | (1,512) | 6,976 |
Item 1. Financial Statements
FAQ
- What is Orthofix Medical Inc.'s R&D?
- Orthofix Medical Inc. (OFIX) reported R&D of $15.94M in Q2 2026.
- How has Orthofix Medical Inc.'s R&D changed year-over-year?
- Orthofix Medical Inc.'s R&D increased by 0.1% year-over-year, from $15.93M to $15.94M.
- What is the long-term trend for Orthofix Medical Inc.'s R&D?
- Over 4 years (2021 to 2025), Orthofix Medical Inc.'s R&D has grown at a 7.3% compound annual growth rate (CAGR), from $49.62M to $65.85M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Orthofix Medical Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude